Spots Global Cancer Trial Database for er+ breast cancer
Every month we try and update this database with for er+ breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) | NCT02580448 | Cancer of the B... Breast Cancer Advanced Breast... Metastatic Brea... Male Breast Can... Triple Negative... ER+ Breast Canc... | Seviteronel | 18 Years - | Innocrin Pharmaceutical | |
| Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Women With Early Breast Cancer | NCT06407401 | ER+ Breast Canc... HER2-negative B... Breast Cancer S... Breast Cancer S... Breast Cancer S... Drug-Related Si... Musculoskeletal... | Duloxetine 60 M... Furosemide 40 m... Booklet for hea... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Tamoxifen Prediction Study in Patients With ER+ Breast Cancer | NCT05525481 | ER+ Breast Canc... | Tamoxifen | 18 Years - | Erasmus Medical Center | |
| Alcohol and Breast Cancer (ABC) Trial | NCT05423730 | ER+ Breast Canc... Breast Cancer Aromatase Inhib... | White Wine Grape Juice | 21 Years - 90 Years | Beth Israel Deaconess Medical Center | |
| Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing | NCT00828854 | ER+ Breast Canc... | Entinostat Aromatase Inhib... | - | Syndax Pharmaceuticals | |
| Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients | NCT01202591 | FGFR Inhibition... ER+ Breast Canc... | AZD4547 Exemestane Placebo Fulvestrant | 18 Years - 99 Years | AstraZeneca | |
| Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers | NCT02734615 | Advanced or Met... | LSZ102 LEE011 BYL719 | 18 Years - | Novartis | |
| Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Women With Early Breast Cancer | NCT06407401 | ER+ Breast Canc... HER2-negative B... Breast Cancer S... Breast Cancer S... Breast Cancer S... Drug-Related Si... Musculoskeletal... | Duloxetine 60 M... Furosemide 40 m... Booklet for hea... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing | NCT00828854 | ER+ Breast Canc... | Entinostat Aromatase Inhib... | - | Syndax Pharmaceuticals | |
| A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer | NCT05534438 | Oligometastatic... Breast Cancer Metastatic Brea... Metastatic Brea... ER+ Breast Canc... HER2+ Breast Ca... | Stereotactic bo... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer | NCT02820961 | Breast Cancer Estrogen Recept... | entinostat exemestane | 18 Years - 85 Years | Syndax Pharmaceuticals | |
| Tamoxifen Prediction Study in Patients With ER+ Breast Cancer | NCT05525481 | ER+ Breast Canc... | Tamoxifen | 18 Years - | Erasmus Medical Center | |
| A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers | NCT02238808 | Estrogen Recept... | Estradiol | 55 Years - | AHS Cancer Control Alberta | |
| Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Women With Early Breast Cancer | NCT06407401 | ER+ Breast Canc... HER2-negative B... Breast Cancer S... Breast Cancer S... Breast Cancer S... Drug-Related Si... Musculoskeletal... | Duloxetine 60 M... Furosemide 40 m... Booklet for hea... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer | NCT04360941 | Triple Negative... Locally Advance... Recurrent Breas... Metastatic Brea... ER+ Breast Canc... HER2-positive B... | Palbociclib Avelumab | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels | NCT04312347 | ER+ Breast Canc... | Tamoxifen dose ... | 18 Years - | Nalagenetics Pte Ltd | |
| Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels | NCT04312347 | ER+ Breast Canc... | Tamoxifen dose ... | 18 Years - | Nalagenetics Pte Ltd | |
| TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer | NCT02586675 | Breast Cancer Breast Cancer -... Breast Cancer -... | Tamoxifen Ribociclib Goserelin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer | NCT02586675 | Breast Cancer Breast Cancer -... Breast Cancer -... | Tamoxifen Ribociclib Goserelin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer | NCT05534438 | Oligometastatic... Breast Cancer Metastatic Brea... Metastatic Brea... ER+ Breast Canc... HER2+ Breast Ca... | Stereotactic bo... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer | NCT02586675 | Breast Cancer Breast Cancer -... Breast Cancer -... | Tamoxifen Ribociclib Goserelin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | NCT06395519 | Advanced or Met... Breast Cancer Ovarian Cancer Prostate Cancer Epithelial Ovar... BRCA2 Mutation ER+ Breast Canc... Castrate Resist... BRCA1 Mutation BRCA Mutation Endometrial Can... Colorectal Canc... Gastric Cancer | ETX-19477 | 18 Years - | 858 Therapeutics, Inc. | |
| A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer | NCT04985266 | ER+ Breast Canc... HER2-negative B... | Palbociclib 125... Fulvestrant inj... Tamoxifen Letrozole Exemestane Anastrozole | 18 Years - | Royal Marsden NHS Foundation Trust | |
| A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC. | NCT06064812 | Metastatic Brea... Locally Advance... Breast Cancer S... ER+ Breast Canc... | FWD1802 palbocilib | 18 Years - | Forward Pharmaceuticals Co., Ltd. | |
| A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer | NCT05534438 | Oligometastatic... Breast Cancer Metastatic Brea... Metastatic Brea... ER+ Breast Canc... HER2+ Breast Ca... | Stereotactic bo... | 18 Years - | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
